Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr788 Inhibitors

Olr788 inhibitors represent a class of chemical compounds that specifically interact with and modulate the activity of the Olr788 receptor, a member of the olfactory receptor family. These receptors, primarily recognized for their role in olfaction, are G protein-coupled receptors (GPCRs) that reside within the cell membrane and facilitate signal transduction through the activation of G proteins. Olr788, like other olfactory receptors, exhibits a unique structure characterized by seven transmembrane helices, which form a binding pocket for various ligands. Inhibitors targeting Olr788 typically function by binding to this receptor's active site or allosteric sites, preventing the receptor from interacting with its natural ligands. This inhibition can alter the receptor's conformation, effectively blocking the downstream signaling pathways initiated upon ligand binding.

The design and synthesis of Olr788 inhibitors involve sophisticated chemical methodologies aimed at achieving high specificity and affinity for the target receptor. These inhibitors often feature complex molecular frameworks that facilitate strong interactions with the receptor, such as hydrogen bonding, van der Waals forces, and hydrophobic interactions. Advanced techniques in computational chemistry and molecular modeling are employed to predict the binding modes and optimize the pharmacophoric features of these inhibitors. Additionally, various strategies such as high-throughput screening and structure-activity relationship (SAR) studies are used to identify potent compounds from large chemical libraries. By understanding the precise molecular interactions between Olr788 and its inhibitors, researchers can elucidate the underlying mechanisms of receptor function and inhibition, contributing to the broader field of receptor biology and chemical signaling.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

Inhibits mTOR, potentially impacting cell growth and proliferation.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor, may disrupt epidermal growth factor signaling.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets RAF kinases, might affect cell proliferation and angiogenesis.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, could modulate cytokine signaling and immune response.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGFR, PDGFR, and KIT, potentially affecting angiogenesis and cell growth.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

BCR-ABL inhibitor, might affect leukemia cell proliferation and survival.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, could induce apoptosis in cancer cells.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

MEK inhibitor, may disrupt MAPK/ERK signaling affecting cell growth.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

Irreversible EGFR inhibitor, potentially affecting cell proliferation in certain cancers.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Inhibits MET, VEGFR, and AXL, could influence cell survival and angiogenesis.